NCT06524570View on ClinicalTrials.gov

Treatment of Cancer with Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

August 1, 2030

Study Completion Date

August 1, 2030

Conditions

CancerMetastatic Cancer

Interventions

DEVICE

HIFU-HT

High-Intensify Focused Ultrasound Histotripsy

DRUG

ICI

Ipilimumab and nivolumab

Trial Locations (1)

Unknown

University Medical Center Utrecht, Utrecht

All Listed Sponsors

lead

UMC Utrecht

OTHER

NCT06524570 - Treatment of Cancer with Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy | Biotech Hunter | Biotech Hunter